Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. AMC
10. META

Go back to Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
(NASDAQ: NVCR) Delayed: 16.53 -0.16 (0.96%)
Previous Close $16.69    52 Week High $28.95 
Open $16.87    52 Week Low $5.95 
Day High $16.87    P/E N/A 
Day Low $16.37    EPS $0.00 
Volume 629,457